Stock listing
NASDAQ:MXCT MaxCyte, Inc. Stock
Home listing (NASDAQ) of MaxCyte, Inc.
Follow MaxCyte, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MXCT
$1.37 USD +0.12 (+9.6%)
Close on Nov 20, 2026
- Day range
- $1.27 – $1.42 USDNov 20, 2026
- Volume
- 1.11M sharesNov 20, 2026
- Market cap
- $141.5M USDAt the close on Nov 20, 2026 · price × 103.3M shares outstanding
- 52-week range
- $0.643 – $1.80 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.31M USDMedian day 542,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MXCT · Home | $1.37 USD | +0.12 (+9.6%) | 1,108,161 | $1.29 | $1.42 | $1.27 | $1.25 | Close on Nov 20, 2026 |
| Frankfurt:MYE0 | €1.13 EUR | -0.03 (-2.6%) | — | €1.13 | €1.13 | €1.13 | €1.16 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MXCT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.37 | +0.12 | +9.6% | $1.29 | $1.42 | $1.27 | 1,108,161 | |
| $1.25 | +0.08 | +6.8% | $1.17 | $1.26 | $1.135 | 968,878 | |
| $1.17 | -0.01 | -0.8% | $1.19 | $1.255 | $1.16 | 1,259,643 | |
| $1.18 | -0.01 | -0.8% | $1.17 | $1.279 | $1.155 | 1,959,184 | |
| $1.19 | 0.00 | 0.0% | $1.16 | $1.20 | $1.12 | 1,247,563 | |
| $1.19 | +0.09 | +8.2% | $1.11 | $1.22 | $1.02 | 2,063,261 | |
| $1.10 | -0.03 | -2.7% | $1.12 | $1.205 | $1.10 | 2,122,752 | |
| $1.13 | -0.17 | -13.1% | $1.40 | $1.42 | $1.08 | 4,482,497 | |
| $1.30 | +0.04 | +3.2% | $1.25 | $1.349 | $1.25 | 1,599,619 | |
| $1.26 | -0.05 | -3.8% | $1.31 | $1.36 | $1.24 | 876,113 | |
| $1.31 | -0.08 | -5.8% | $1.39 | $1.421 | $1.29 | 873,628 | |
| $1.39 | -0.07 | -4.8% | $1.47 | $1.48 | $1.36 | 855,958 | |
| $1.46 | +0.01 | +0.7% | $1.51 | $1.51 | $1.365 | 1,031,419 | |
| $1.45 | -0.14 | -8.8% | $1.59 | $1.70 | $1.43 | 1,283,635 | |
| $1.59 | -0.14 | -8.1% | $1.71 | $1.72 | $1.505 | 963,558 | |
| $1.73 | +0.02 | +1.2% | $1.71 | $1.76 | $1.623 | 1,138,996 | |
| $1.71 | +0.17 | +11.0% | $1.54 | $1.73 | $1.502 | 1,706,103 | |
| $1.54 | +0.03 | +2.0% | $1.51 | $1.64 | $1.51 | 1,577,609 | |
| $1.51 | +0.11 | +7.9% | $1.39 | $1.53 | $1.365 | 1,128,680 | |
| $1.40 | -0.03 | -2.1% | $1.43 | $1.43 | $1.35 | 757,400 | |
| $1.43 | -0.04 | -2.7% | $1.44 | $1.51 | $1.43 | 1,018,800 | |
| $1.47 | +0.04 | +2.8% | $1.42 | $1.53 | $1.405 | 1,423,100 | |
| $1.43 | +0.13 | +10.0% | $1.29 | $1.457 | $1.29 | 1,388,100 | |
| $1.30 | 0.00 | 0.0% | $1.30 | $1.31 | $1.27 | 986,400 | |
| $1.30 | 0.00 | 0.0% | $1.32 | $1.32 | $1.28 | 1,009,500 | |
| $1.30 | +0.05 | +4.0% | $1.27 | $1.31 | $1.255 | 3,792,300 | |
| $1.25 | +0.286 | +29.7% | $1.225 | $1.33 | $1.195 | 12,670,100 | |
| $0.964 | -0.031 | -3.1% | $0.981 | $1.01 | $0.936 | 327,900 | |
| $0.995 | -0.015 | -1.5% | $1.01 | $1.01 | $0.972 | 150,000 | |
| $1.01 | -0.01 | -1.0% | $1.02 | $1.03 | $0.99 | 240,000 | |
| $1.02 | -0.02 | -1.9% | $1.04 | $1.04 | $0.964 | 476,800 | |
| $1.04 | -0.05 | -4.6% | $1.07 | $1.08 | $1.04 | 311,900 | |
| $1.09 | +0.01 | +0.9% | $1.09 | $1.105 | $1.05 | 333,100 | |
| $1.08 | +0.01 | +0.9% | $1.08 | $1.10 | $1.06 | 194,900 | |
| $1.07 | -0.02 | -1.8% | $1.11 | $1.11 | $1.07 | 228,100 | |
| $1.09 | -0.03 | -2.7% | $1.12 | $1.16 | $1.08 | 397,100 | |
| $1.12 | -0.06 | -5.1% | $1.19 | $1.20 | $1.12 | 346,500 | |
| $1.18 | +0.02 | +1.7% | $1.18 | $1.23 | $1.16 | 542,900 | |
| $1.16 | -0.01 | -0.9% | $1.16 | $1.17 | $1.14 | 284,700 | |
| $1.17 | -0.02 | -1.7% | $1.20 | $1.20 | $1.16 | 415,900 | |
| $1.19 | 0.00 | 0.0% | $1.19 | $1.21 | $1.17 | 231,700 | |
| $1.19 | -0.05 | -4.0% | $1.24 | $1.24 | $1.19 | 251,700 | |
| $1.24 | +0.02 | +1.6% | $1.22 | $1.25 | $1.20 | 259,700 | |
| $1.22 | +0.03 | +2.5% | $1.19 | $1.24 | $1.18 | 471,800 | |
| $1.19 | -0.005 | -0.4% | $1.19 | $1.21 | $1.16 | 485,200 | |
| $1.195 | +0.015 | +1.3% | $1.21 | $1.23 | $1.19 | 257,600 | |
| $1.18 | -0.01 | -0.8% | $1.20 | $1.23 | $1.171 | 299,400 | |
| $1.19 | +0.015 | +1.3% | $1.18 | $1.20 | $1.171 | 272,100 | |
| $1.175 | +0.015 | +1.3% | $1.19 | $1.19 | $1.13 | 517,700 | |
| $1.16 | -0.03 | -2.5% | $1.20 | $1.21 | $1.16 | 331,400 | |
| $1.19 | -0.03 | -2.5% | $1.22 | $1.23 | $1.18 | 300,500 | |
| $1.22 | -0.055 | -4.3% | $1.29 | $1.29 | $1.22 | 394,000 | |
| $1.275 | -0.005 | -0.4% | $1.29 | $1.29 | $1.25 | 432,900 | |
| $1.28 | +0.02 | +1.6% | $1.25 | $1.30 | $1.25 | 333,500 | |
| $1.26 | -0.01 | -0.8% | $1.27 | $1.27 | $1.22 | 425,900 | |
| $1.27 | +0.03 | +2.4% | $1.24 | $1.305 | $1.22 | 502,300 | |
| $1.24 | -0.05 | -3.9% | $1.26 | $1.28 | $1.215 | 678,900 | |
| $1.29 | +0.07 | +5.7% | $1.19 | $1.315 | $1.19 | 777,300 | |
| $1.22 | -0.06 | -4.7% | $1.30 | $1.30 | $1.21 | 563,100 | |
| $1.28 | -0.03 | -2.3% | $1.31 | $1.325 | $1.28 | 360,000 | |
| $1.31 | -0.04 | -3.0% | $1.35 | $1.35 | $1.31 | 291,900 | |
| $1.35 | -0.04 | -2.9% | $1.38 | $1.39 | $1.34 | 310,488 | |
| $1.39 | +0.01 | +0.7% | $1.36 | $1.40 | $1.35 | 620,491 | |
| $1.38 | 0.00 | 0.0% | $1.40 | $1.40 | $1.355 | 435,800 | |
| $1.38 | -0.01 | -0.7% | $1.39 | $1.405 | $1.36 | 611,800 |
- Ticker
- NASDAQ:MXCT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
Latest earnings call · Nov 10, 2026
MaxCyte (NASDAQ:MXCT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 10, 2026
Investor Presentation (November 2026)
Investor deck · 29 slides
Latest news
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
Nov 10, 2026
Closed $1.13 (-13.1%) on Nov 10, 2026
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
Nov 10, 2026
Closed $1.13 (-13.1%) on Nov 10, 2026
MaxCyte to Participate in Three Upcoming Investor Conferences
Oct 28, 2026
Closed $1.71 (+11.0%) on Oct 28, 2026
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
Oct 14, 2026
Closed $1.25 (+29.7%) on Oct 14, 2026
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
Sep 23, 2026
Closed $1.19 (-4.0%) on Sep 23, 2026
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
Aug 19, 2026
Closed $1.39 (+9.4%) on Aug 19, 2026
MaxCyte Reports Second Quarter 2026 Financial Results
Aug 12, 2026
Closed $1.39 (+9.4%) on Aug 13, 2026
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Jul 21, 2026
Closed $1.23 (+5.1%) on Jul 21, 2026
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
Jul 15, 2026
Closed $1.35 (-4.9%) on Jul 16, 2026
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
May 12, 2026
Closed $1.02 (+24.1%) on May 13, 2026
MaxCyte, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 17 in the last 12 months · 96 in all · newest Nov 10, 2026 · oldest 2021
- Calls
- 22 calls with a replay · 22 with a transcript · latest Nov 10, 2026
- Decks
- 18 decks · latest Nov 10, 2026
Where MaxCyte, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MXCT · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A2AGVE | LS Exchange | Germany | EUR |
| BOATS:MXCT | BOATS | United States | USD |
| Lang & Schwarz:A2AGVE | Lang & Schwarz | Germany | EUR |
| gettex:MYE0 | gettex | Germany | EUR |
| Tradegate:MYE0 | Tradegate | Germany | EUR |
| Dusseldorf:MYE0 | Dusseldorf | Germany | EUR |
| Frankfurt:MYE0 | Frankfurt | Germany | EUR |
| Munich:MYE0 | Munich | Germany | EUR |
| Stuttgart:MYE0 | Stuttgart | Germany | EUR |
Valuation
EV/sales 1.7× against a median of 6.0×: 4th lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $57.06M USD
- P/E
- Loss
- EV/sales
- 1.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- 81.0%
- Operating margin
- −98.0%
- Net margin
- −81.4%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.93
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MaxCyte, Inc. · NASDAQ:MXCT | US$141.5M | US$57.06M | n/a | 1.7× | n/a | 0.9× | −81.4% | 0.1× | 0.93 |
| Boditech Med, Inc. · KRX:206640 | US$152.9M | US$121.7M | 7.9× | 0.9× | 4.4× | 0.8× | 14.8% | 0.0× | n/a |
| Genovis AB · OMXSTO:GENO | US$150.1M | US$142.7M | 74.9× | 10.8× | 41.7× | 5.0× | 15.1% | 0.3× | n/a |
| Genomictree, Inc. · KRX:228760 | US$148.6M | US$89.43M | n/a | 40.6× | n/a | 1.6× | −306.4% | 0.0× | n/a |
| Anbio Biotechnology · NASDAQ:NNNN | US$145.7M | US$133.8M | 22.8× | 15.5× | n/a | 4.8× | 74.1% | 0.0× | 0.56 |
| Shanghai Rightongene Biotechnology Co. Ltd. Class A · SSE:688217 | US$139.0M | US$102.4M | n/a | 4.6× | n/a | 1.1× | −43.9% | 0.0× | n/a |
| EKF Diagnostics Holdings plc · LSE:EKF | US$134.4M | US$115.4M | 48.4× | 1.7× | 7.1× | 1.5× | 4.1% | 0.0× | n/a |
| Bioventix PLC · LSE:BVXP | US$133.3M | US$126.3M | 13.4× | 7.4× | 9.7× | 9.2× | 57.8% | 0.0× | n/a |
| Curiosis, Inc. · KRX:494120 | US$131.9M | US$118.3M | n/a | 18.7× | n/a | 7.1× | −93.3% | 0.0× | n/a |
| Bioneer Corporation · KRX:064550 | US$128.3M | US$107.8M | n/a | 0.4× | 10.0× | 0.8× | −1.9% | 0.3× | n/a |
| Fine Foods & Pharmaceuticals N.T.M. SpA · MIL:FF | US$123.5M | US$174.6M | 11.1× | 0.6× | 4.6× | 0.8× | 4.0% | 0.6× | n/a |
| Median of the others | US$136.7M | US$120.0M | 18.1× | 6.0× | 8.4× | 1.6× | 4.0% | 0.0× | 0.56 |
Forecasts
5 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.11 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.27 · 4 analysts
- Revenue, year to Dec 2026
- 34.55M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Maher Masoud | President and Chief Executive Officer |
| Parmeet Ahuja | Chief Financial Officer |
| David Deuchler | Investor Relations |
| Ana-Paula Martins Fernandes | Senior Vice President, Global Sales |
| Jill Mayer | Senior Vice President of Human Resources |
| Jay Gelfman | Chief Operations Officer |
| Sidharth Kapileshwar | Chief Corporate Development Officer |
Board
| Director | Role |
|---|---|
| Richard Douglas | Non-Executive Chairman |
| Cynthia Collins | Non-Executive Director |
| John Johnston | Non-Executive Director |
| Maher Masoud | President and Chief Executive Officer |
| Patrick Balthrop | Non-Executive Director |
| Rekha Hemrajani | Non-Executive Director |
| Stan Erck | Non-Executive Director |
| Will Brooke | Non-Executive Director |
| Yasir Al-Wakeel | Non-Executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| MaxCyte (NASDAQ:MXCT) Q3 2026 Earnings Call | Tue, Nov 10, 2026 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q1 2026 Earnings Call | Tue, May 12, 2026 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q4 2025 Earnings Call | Tue, Mar 24, 2026 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q1 2025 Earnings Call | Wed, May 07, 2025 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q4 2024 Earnings Call | Tue, Mar 11, 2025 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 4:30 PM ET | Replay |
All 22 calls
| Call | When | Status |
|---|---|---|
| MaxCyte (NASDAQ:MXCT) Q1 2024 Earnings Call | Tue, May 07, 2024 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q4 2023 Earnings Call | Tue, Mar 12, 2024 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q3 2023 Earnings Call | Wed, Oct 04, 2023 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q2 2023 Earnings Call | Wed, Aug 09, 2023 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q1 2023 Earnings Call | Wed, May 10, 2023 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q4 2022 Earnings Call | Wed, Mar 15, 2023 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q3 2022 Earnings Call | Wed, Nov 09, 2022 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q2 2022 Earnings Call | Wed, Aug 10, 2022 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q1 2022 Earnings Call | Mon, May 09, 2022 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q4 2021 Earnings Call | Tue, Mar 22, 2022 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q3 2021 Earnings Call | Wed, Nov 10, 2021 · 4:30 PM ET | Replay |
| MaxCyte (NASDAQ:MXCT) Q2 2021 Earnings Call | Mon, Sep 13, 2021 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −13.1% |
| Q2 2026 | Aug 12, 2026 · After close | +9.4% |
| Q1 2026 | May 13, 2026 | +32.6% |
| Q4 2025 | Mar 24, 2026 · After close | −6.8% |
| Q3 2025 | Nov 12, 2025 · After close | −4.4% |
| Q2 2025 | Aug 6, 2025 · After close | −29.9% |
| Q1 2025 | May 7, 2025 · After close | −11.3% |
| Q4 2024 | Mar 11, 2025 | −7.0% |
| Q3 2024 | Nov 6, 2024 · After close | −10.8% |
| Q2 2024 | Aug 6, 2024 · After close | −8.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | +18.1% |
| Q4 2023 | Mar 12, 2024 · After close | +4.5% |
| Q3 2023 | Nov 8, 2023 · After close | −3.3% |
| Q2 2023 | Aug 9, 2023 · After close | −10.4% |
| Q1 2023 | May 10, 2023 · After close | −19.8% |
| Q4 2022 | Mar 15, 2023 · After close | +6.4% |
| Q3 2022 | Nov 9, 2022 · After close | +15.7% |
| Q2 2022 | Aug 10, 2022 · After close | +1.6% |
| Q1 2022 | May 9, 2022 · After close | −0.6% |
| Q4 2021 | Mar 22, 2022 · After close | +3.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 29 slides | Nov 10, 2026 |
| Merger or Acquisition (November 2026) | Merger or acquisition | 14 slides | Nov 10, 2026 |
| Investor Presentation (August 2026) | Investor deck | 29 slides | Aug 12, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 10 slides | Aug 12, 2026 |
| Investor Presentation (May 2026) | Investor deck | 27 slides | May 12, 2026 |
| Investor Presentation (March 2026) | Investor deck | 27 slides | Mar 24, 2026 |
| Investor Presentation (November 2025) | Investor deck | 27 slides | Nov 12, 2025 |
| Investor Presentation (August 2025) | Investor deck | 27 slides | Aug 6, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 38 slides | Aug 6, 2025 |
| Investor Presentation (May 2025) | Investor deck | 26 slides | May 7, 2025 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2025) | Investor deck | 26 slides | Mar 11, 2025 |
| Investor Presentation (November 2024) | Investor deck | 20 slides | Nov 6, 2024 |
| Investor Presentation (August 2024) | Investor deck | 19 slides | Aug 6, 2024 |
| Investor Presentation (May 2024) | Investor deck | 21 slides | May 7, 2024 |
| Corporate Update (January 2021) | Corporate update | 17 slides | January 2021 |
| Investor Presentation (January 2021) | Investor deck | 16 slides | January 2021 |
| H1 2020 Earnings Presentation | Earnings | 24 slides | September 2020 |
| Technical Presentation (2007) | Technical | 26 slides | 2007 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.0M | 38.6M | 41.3M | 44.3M | 33.9M | 26.2M | 21.6M | 16.7M | 14.0M | 12.3M |
| Cost of revenue | 6.22M | 7.10M | 4.74M | 5.10M | 3.65M | 2.77M | 2.50M | 1.84M | 1.45M | 1.31M |
| Gross profit | 26.8M | 31.5M | 36.5M | 39.2M | 30.2M | 23.4M | 19.1M | 14.8M | 12.5M | 11.0M |
| Research and development | 20.8M | 22.2M | 23.8M | 19.5M | 15.4M | 17.7M | 17.6M | 11.2M | 11.3M | 4.70M |
| Selling, general and administrative | 28.1M | 29.7M | 30.1M | 25.8M | 18.7M | 7.37M | 5.56M | 5.28M | 4.52M | 4.20M |
| Operating income | -51.9M | -51.2M | -48.3M | -27.4M | -18.2M | -11.1M | -12.4M | -8.42M | -9.29M | -2.72M |
| Depreciation and amortization | 4.34M | 4.32M | 4.17M | 2.70M | 1.42M | 1.05M | 613.5K | 344.0K | 142.9K | 105.7K |
| EBITDA | -47.6M | -46.9M | -44.1M | -24.7M | -16.8M | -10.0M | -11.8M | -8.08M | -9.15M | -2.62M |
| Interest expense | 126.9K | 5.40K | 21.7K | 51.9K | 614.6K | 625.3K | 637.8K | |||
| Income before tax | -44.6M | -41.1M | -37.9M | -23.6M | -19.1M | -11.8M | -12.9M | -8.87M | -9.92M | -3.35M |
| Income tax | 4.00M | -3.79M | 0 | 0 | 0 | 170.3K | 653.5K | |||
| Net income | -44.6M | -41.1M | -37.9M | -23.6M | -19.1M | -11.8M | -12.9M | -8.87M | -9.92M | -3.35M |
| Earnings per share, basic | -0.42 | -0.39 | -0.37 | -0.23 | -0.21 | -0.17 | -0.23 | -0.17 | -0.20 | -0.10 |
| Earnings per share, diluted | -0.42 | -0.39 | -0.37 | -0.23 | -0.21 | -0.17 | -0.23 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 20.1M | 27.9M | 46.5M | 11.1M | 47.8M | 18.8M | 15.2M | 11.2M | 25.3M | 11.7M |
| Short-term investments | 83.0M | 126.6M | 121.8M | 216.3M | 207.3M | 16.0M | 1.50M | 3.19M | ||
| Receivables | 3.50M | 4.68M | 5.78M | 11.2M | 6.88M | 5.17M | 3.24M | 4.90M | 3.20M | 2.41M |
| Inventory | 7.55M | 8.91M | 12.2M | 8.58M | 5.20M | 4.32M | 3.70M | 2.24M | 1.35M | 1.33M |
| Current assets | 118.4M | 171.7M | 190.2M | 252.3M | 270.4M | 45.3M | 24.5M | 22.4M | 30.6M | 15.8M |
| Property, plant and equipment | 17.5M | 19.7M | 23.5M | 23.7M | 7.68M | 4.55M | 5.53M | 1.82M | 847.6K | |
| Total assets | 202.5M | 239.5M | 268.3M | 286.7M | 284.1M | 51.8M | 30.0M | 24.3M | 31.4M | 16.1M |
| Accounts payable | 1.40M | 1.36M | 743.0K | 292.0K | 1.82M | 890.2K | 2.09M | 4.12M | 4.33M | 3.17M |
| Current liabilities | 14.3M | 15.8M | 17.9M | 15.4M | 15.6M | 11.6M | 9.34M | 6.57M | 7.24M | 5.65M |
| Long-term debt | 4.92M | 4.90M | 5.06M | 4.18M | ||||||
| Total debt | 17.9M | 18.0M | 18.7M | 16.1M | 5.68M | 6.97M | 7.21M | 5.06M | 5.03M | 5.01M |
| Total liabilities | 31.0M | 33.2M | 36.1M | 32.7M | 21.2M | 18.6M | 16.4M | 12.0M | 11.8M | 11.0M |
| Shareholders' equity | 171.5M | 206.3M | 232.2M | 254.0M | 262.9M | 33.2M | 13.6M | 12.3M | 19.6M | 5.08M |
| Shares outstanding | 106.8M | 105.7M | 104.0M | 102.4M | 101.2M | 77.4M | 101.5M | 51.2M | 48.6M | 33.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -34.4M | -27.6M | -21.7M | -14.8M | -10.7M | -8.78M | -8.80M | -10.5M | -9.68M | -2.33M |
| Capital spending | -1.77M | -1.65M | -3.70M | -18.5M | -3.83M | -2.07M | -1.27M | -709.7K | -609.7K | -218.8K |
| Free cash flow | -36.2M | -29.3M | -25.4M | -33.3M | -14.5M | -10.9M | -10.1M | -11.2M | -10.3M | -2.55M |
| Cash from investing | 25.9M | 6.93M | 55.0M | -24.8M | -195.0M | -16.6M | 454.5K | -3.83M | -609.7K | -218.8K |
| Cash from financing | 656.0K | 2.06M | 2.14M | 2.89M | 234.7M | 28.9M | 12.3M | 226.8K | 23.9M | 11.9M |
| Share buybacks | 459.0K | 269.0K | 2.89M | 239.7M | ||||||
| Change in cash | -7.82M | -18.6M | 35.4M | -36.7M | 29.0M | 3.54M | 3.96M | -14.1M | 13.6M | 9.32M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 2, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 16, 2026 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 15, 2026 | Offer document | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 27, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2026 | Results | SEC |
| 8-K · Current report | Mar 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 3, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 24, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 22, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 26, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Management or board change | SEC |
| DEFA14A · Additional proxy material | May 29, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 15, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 27, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Dec 26, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 31, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 21, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 15, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 26, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| ARS · Annual report to shareholders | May 1, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Mar 25, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 12, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2024 | Results | SEC |
| 8-K · Current report | Mar 5, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 26, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 1, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 26, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 28, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Dec 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 29, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 29, 2023 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 17, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 16, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 14, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 8-K · Current report | Oct 4, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 30, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 10, 2023 | Other filings | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2023 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2023 | Results | SEC |
| 4 · Change in ownership | May 5, 2023 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2023 | Insider trade | SEC |
This page holds 200 of 339 filings. Open Filings
Cap table
Built by 6ix from MaxCyte, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 103,250,292
- Fully diluted
- 103,250,292
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 103,250,292 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 103,250,292 |
| Sep 30, 2026 | 103,233,238 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rekha Hemrajani Other companies: LB Pharmaceuticals Inc (Director · Since at least Sep 10, 2025); BioAge Labs, Inc. (Director · Since at least Apr 17, 2024); ALX Oncology Holdings Inc. (Director · Since at least Jun 15, 2022) | Non-Executive Director · Since at least Jun 29, 2022 |
| Cynthia Collins Other companies: Certara, Inc. (Director · Since at least May 21, 2025); Codexis, Inc. (Director · Since at least Mar 28, 2025) | Director · Since at least Jun 18, 2025 |
| Richard H. Douglas Other companies: Novavax, Inc. (Director · Since at least Jun 20, 2026); Aldeyra Therapeutics, Inc. (Director · Since at least Jun 10, 2026) | Director · Since at least Dec 22, 2024 |
| Douglas J. Swirsky Other companies: Cellectar Biosciences, Inc. (Director · Since at least Jun 14, 2024) | CHIEF FINANCIAL OFFICER · Since at least Mar 15, 2024 |
| Ali Soleymannezhad | Chief Commercial Officer · Sep 11, 2024 – Mar 18, 2025 · Past |
| Amanda Louise Murphy | Chief Financial Officer · Jul 29, 2021 – Mar 25, 2022 · Past |
| Ana-Paula Martins Fernandes | Senior Vice President, Global Sales · Since at least Nov 5, 2026 |
| David Deuchler | Investor Relations · Since at least Jan 12, 2026 |
| Jay Gelfman | Chief Operations Officer · Since at least Nov 5, 2026 |
| Jill Mayer | Senior Vice President of Human Resources · Since at least Nov 5, 2026 |
All 22 people
| Person | Seat |
|---|---|
| John Johnston | Non-Executive Director · Since at least Jun 22, 2026 |
| Maher Masoud | President and Chief Executive Officer · Since at least Jul 29, 2021 |
| Parmeet Ahuja | Chief Financial Officer · Since at least Mar 31, 2026 |
| Patrick Balthrop | Non-Executive Director · Since at least Jun 22, 2026 |
| Ron Holtz | Chief Financial Officer · Jul 29, 2021 – Mar 20, 2023 · Past |
| Sidharth Kapileshwar | Chief Corporate Development Officer · Since at least Sep 23, 2026 |
| Stan Erck | Non-Executive Director · Since at least Jun 22, 2026 |
| Stanley C Erck | Director · Since at least Jun 18, 2025 |
| Thomas M Ross | EVP, GLOBAL SALES · Jul 29, 2021 – Aug 1, 2024 · Past |
| Will Brooke | Non-Executive Director · Since at least Jun 22, 2026 |
| William W Brooke | Director · Since at least Jun 18, 2025 |
| Yasir Al-Wakeel | Director · Since at least Jun 11, 2024 |
Log in to ask 6ix AI your own questions about MaxCyte, Inc.